Literature DB >> 17394152

Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.

Jeremy R Parfitt1, Paul Marotta, Mohammed Alghamdi, William Wall, Anand Khakhar, Neville G Suskin, Douglas Quan, Vivian McAllister, Cam Ghent, Mark Levstik, Carolyn McLean, Subrata Chakrabarti, Bertha Garcia, David K Driman.   

Abstract

Milan and University of California at San Francisco (UCSF) criteria are used to select patients with hepatocellular carcinoma (HCC) for liver transplantation (LT). Recurrent HCC is a significant cause of death. There is no widely accepted pathological assessment strategy to predict recurrent HCC after transplantation. This study compares the pathology of patients meeting Milan and UCSF criteria and develops a pathological score and nomogram to assess the risk of recurrent HCC after transplantation. All explanted livers with HCC from our center over the 18-yr period 1985 to 2003 were assessed for multiple pathological features and relevant clinical data were recorded; multivariate analysis was performed to determine features associated with recurrent HCC. Using pathological variables that independently predicted recurrent HCC, a pathological score and nomogram were developed to determine the probability of recurrent HCC. Of 75 cases analyzed, 50 (67%) met Milan criteria, 9 (12%) met only UCSF criteria and 16 (21%) met neither criteria based on explant pathology. There were 20 cases of recurrent HCC and the mean follow-up was 8 yr. Recurrent HCC was more common (67 vs. 12%; P < 0.001) and survival was lower (15 vs. 83% at 5 yr; 15 vs. 55% at 8 yr; P < 0.001) with those who met only UCSF criteria, compared to those who met Milan criteria. Cryptogenic cirrhosis (25 vs. 5%; P = 0.015), preoperative AFP >1,000 ng/mL (20 vs. 0%; P < 0.001) and postoperative OKT3 use (40 vs. 15%; P = 0.017) were more common among patients with recurrent HCC. While microvascular invasion was the strongest pathological predictor of recurrent HCC, tumor size >or=3 cm (P = 0.004; odds ratio [OR] = 7.42), nuclear grade (P = 0.044; OR = 3.25), microsatellitosis (P = 0.020; OR = 4.82), and giant/bizarre cells (P = 0.028; OR = 4.78) also predicted recurrent HCC independently from vascular invasion. The score and nomogram stratified the risk of recurrent HCC into 3 tiers: low (<5%), intermediate (40-65%), and high (>95%). In conclusion, compared to patients meeting Milan criteria, patients who meet only UCSF criteria have a worse survival and an increased rate of recurrent HCC with long-term follow-up, as well as more frequent occurrence of adverse histopathological features, such as microvascular invasion. Application of a pathological score and nomogram could help identify patients at increased risk for tumor recurrence, who may benefit from increased surveillance or adjuvant therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17394152     DOI: 10.1002/lt.21078

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  43 in total

1.  Obesity and microvascular invasion in hepatocellular carcinoma.

Authors:  Abby B Siegel; Shuang Wang; Judith S Jacobson; Dawn L Hershman; Emerson A Lim; Jeanette Yu; Lauren Ferrante; Kalpana M Devaraj; Helen Remotti; Shannon Scrudato; Karim Halazun; Jean Emond; Lorna Dove; Robert S Brown; Alfred I Neugut
Journal:  Cancer Invest       Date:  2010-12       Impact factor: 2.176

2.  Wading through the noise of "multi-omics" to identify prognostic biomarkers in hepatocellular carcinoma.

Authors:  Karen Pineda-Solis; Vivian McAlister
Journal:  Hepatobiliary Surg Nutr       Date:  2015-08       Impact factor: 7.293

3.  In vitro three dimensional culture of hepatocellular carcinoma to measure prognosis and responsiveness to chemotherapeutic agents.

Authors:  Brad Shrum; Penny Costello; Warren McDonald; Christopher Howlett; Marisa Donnelly; Vivian C McAlister
Journal:  Hepatobiliary Surg Nutr       Date:  2016-06       Impact factor: 7.293

Review 4.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

5.  Gene-expression signature of vascular invasion in hepatocellular carcinoma.

Authors:  Beatriz Mínguez; Yujin Hoshida; Augusto Villanueva; Sara Toffanin; Laia Cabellos; Swan Thung; John Mandeli; Daniela Sia; Craig April; Jian-Bing Fan; Anja Lachenmayer; Radoslav Savic; Sasan Roayaie; Vincenzo Mazzaferro; Jordi Bruix; Myron Schwartz; Scott L Friedman; Josep M Llovet
Journal:  J Hepatol       Date:  2011-04-13       Impact factor: 25.083

6.  Validity of eleven prognostic scores with respect to intra- and extrahepatic recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  A Bauschke; A Altendorf-Hofmann; H Kissler; A Koch; C Malessa; U Settmacher
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

Review 7.  Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.

Authors:  Trevor W Reichman; Chandra S Bhati; Narendra R Battula
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

8.  Recent advances in liver transplantation for the practicing gastroenterologist.

Authors:  Ranjan Mascarenhas; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2009-06

9.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

10.  Liver Transplantation for HCC: A Review.

Authors:  Rahul Kakodkar; A S Soin
Journal:  Indian J Surg       Date:  2011-12-27       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.